Atovaquone clinical pharmacology

Revision as of 01:03, 7 January 2014 by Gerald Chi (talk | contribs) (Created page with "__NOTOC__ {{Atovaquone}} {{CMG}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = MEPRON (ATOVAQUONE) SUSPENSION [GLAXOSMITHKLINE LLC] | url =ht...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Atovaquone
MEPRON® FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Drug Interactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]



[1]

References

  1. ↑ "MEPRON (ATOVAQUONE) SUSPENSION [GLAXOSMITHKLINE LLC]".

Adapted from the FDA Package Insert.

Retrieved from "https://www.wikidoc.org/index.php?title=Atovaquone_clinical_pharmacology&oldid=926816"